产品
编 号：F041471
分子式：C17H11BrClFN2O4
分子量：441.64
分子式：C17H11BrClFN2O4
分子量：441.64
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 112733-06-9
产品详情
生物活性：
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats.
体内研究：
Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner.Animal Model:Zucker diabetic fatty (ZFD) rats (type 2 diabetes models)
Dosage:3.2, 32 mg/kg
Administration:P.o.; daily for 8 weeks
Result:At 3.2 mg/kg, zenarestat had no significant effect on the delay in F-wave minimal latency (FML) and the slowing of motor nerve conduction velocity (MNCV), although the sorbitol accumulation in the sciatic nerve was partially inhibited in ZDF rats. At 32 mg/kg zenarestat treatment improved these nerve dysfunctions in ZDF rats, along with a reduction of nerve sorbitol accumulation almost to the level of lean rats.
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats.
体内研究：
Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner.Animal Model:Zucker diabetic fatty (ZFD) rats (type 2 diabetes models)
Dosage:3.2, 32 mg/kg
Administration:P.o.; daily for 8 weeks
Result:At 3.2 mg/kg, zenarestat had no significant effect on the delay in F-wave minimal latency (FML) and the slowing of motor nerve conduction velocity (MNCV), although the sorbitol accumulation in the sciatic nerve was partially inhibited in ZDF rats. At 32 mg/kg zenarestat treatment improved these nerve dysfunctions in ZDF rats, along with a reduction of nerve sorbitol accumulation almost to the level of lean rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备